

Special Issue

Novel Advance in COVID-19 and Neuroscience

Message from the Guest Editor

Towards the end of 2019, a new respiratory syndrome, now known as coronavirus disease 2019 (COVID-19), was reported in Wuhan, China. Since then, the SARS-CoV-2 infection has spread globally. Now, after two years of the pandemic, there is robust evidence documenting that COVID-19 extends beyond the pulmonary system. Among all the organs involved, the brain is one of the most severely affected. A steep surge or worsening of neurologic and psychiatric syndromes has been reported during and after SARS-CoV-2 infection, including confusion, depression, anxiety, post-traumatic stress disorder, dementia, and psychosis. However, despite the efforts made to define, classify, and treat COVID-19-related neuropsychiatric diseases, their characteristic underlying neurobiology remains largely unknown. Therefore, the aim of the present Special Issue, published in the *Journal of Personalized Medicine*, is to provide a comprehensive description of the neurological and psychiatric effects of COVID-19. Advances in diagnosis, definition of pathophysiological models, and treatment strategies will be further investigated.


Guest Editor

Dr. Alessio Simonetti

1. Department of Geriatrics, Neuroscience and Orthopedics, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
2. Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA

Deadline for manuscript submissions

closed (25 April 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/118254

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).